Markets
Blue Ozempic pens with yellow measuring tape on pink background.
Ozempic pens with yellow measuring tape (Getty Images)

LifeMD reports earnings miss, weak guidance amid “fierce competition” in GLP-1 market

The company has partnerships with Novo Nordisk and Eli Lilly, the drugmakers behind the blockbuster GLP-1 drugs.

J. Edward Moreno

LifeMD plunged in early trading Tuesday after it reported earnings results on Monday that missed Wall Street estimates, which it attributed in part to “fierce competition from low-price compounded GLP-1 providers.”

The telehealth company reported a loss per share of $0.10, significantly steeper than the $0.02 per-share loss analysts polled by FactSet were expecting. While the company’s sales for Q3 were in line with estimates, it said it expects revenue for the current quarter to hit at most $46 million, compared to the $50.5 million the Street was penciling in.

LifeMD is one of a handful of telehealth companies that have a partnership with both Novo Nordisk and Eli Lilly to sell discounted cash-pay versions of their blockbuster GLP-1 shots through their platform. But copycat versions, sold by companies like Hims & Hers, are still cheaper and tough to compete with on price. Even in the booming GLP-1 market, the company said, its weight management segment contracted slightly quarter over quarter.

“The last two quarters have been challenging in the weight management category due to intense competition from low-cost and in many cases low-quality compounded GLP-1 markers offering prices we cannot and will not match,” LifeMD CEO Justin Schreiber told analysts. “While many of these compounded products are less effective and in some cases unsafe, aggressive marketing and artificially low entry price points have drawn in a portion of consumers and created near-term pressure.”

LifeMD may have a tailwind going forward. The price of branded GLP-1s is starting to come down and oral versions are set to enter the market next year, which could bring a wave of subscribers to its platform.

The same day LifeMD reported earnings, Novo announced that it would slash prices for its cash-pay Wegovy and Ozempic shots, setting them at roughly the same price as compounded versions. Both Lilly and Novo promised the Trump administration they would lower prices on their blockbuster GLP-1 drugs next year.

Hims, for one, has seen its stock price slip on those announcements because it does not have partnerships with those drugmakers and has often been at odds with them. While its copycat versions have boosted sales in the past year, if the price of branded GLP-1s matches its copycat versions, consumers may turn to those.

As the pricing for branded versions falls, companies in good graces with the drugmakers may stand to benefit. “We have consistently believed the branded GLP-1 manufacturers would ultimately reduce pricing to broaden patient access, and that moment is now clearly underway,” LifeMD’s Schreiber said.

More Markets

See all Markets
markets

Report: Boeing could unveil 500-jet order from China during Trump’s visit later this month

Shares of Boeing are up nearly 4% on Friday afternoon, following a Bloomberg report that the company could be close to finalizing a deal to sell 500 planes to China.

The deal was first reported in August and would be one of Boeing’s largest ever.

According to Bloomberg’s sources, the deal could be officially unveiled when President Trump travels to China at the end of the month. That trip could be delayed given the war in Iran. The deal, sources say, could still fall apart — similar language to when it was first reported on more than six months ago.

Boeing has been on the outside of the Chinese market, in terms of new orders, since 2019 amid escalating US-China trade tensions.

According to Bloomberg’s sources, the deal could be officially unveiled when President Trump travels to China at the end of the month. That trip could be delayed given the war in Iran. The deal, sources say, could still fall apart — similar language to when it was first reported on more than six months ago.

Boeing has been on the outside of the Chinese market, in terms of new orders, since 2019 amid escalating US-China trade tensions.

markets

Why software shares are withstanding the war jitters

The outbreak of the war in Iran has clearly rattled investors and created a few clear winners — mostly energy stocks — and losers — consumer staples, airlines, and, well, more or else everything else.

But there is one interesting outlier to that Manichaean market dynamic.

Software shares — often the same companies that the market was giving up for dead just a few weeks ago due to overexpectations of an AI-driven disruption — have been holding up remarkably well.

These companies, including Intuit, ServiceNow, Datadog, Snowflake, IBM, Workday, and Oracle, have actually had a pretty decent run since the war started with a combined US-Israeli attack on Iran last weekend.

A new note from RBC Capital’s Rishi Jaluria suggests this isn’t just a fluke. Looking at the performance of software stocks during periods of geopolitical stress and market volatility over the last 10 and 25 years, his team found that software shares appear fairly well insulated when these broader shocks hit. RBC wrote:

“The defensive nature of SaaS models and the mission-critical nature of many core software systems at the enterprise level (e.g., in the absence of mass layoffs that may create seat-based headwinds, geopolitical uncertainty and/or market volatility typically will not cause an enterprise CIO to consider ripping out their ERP, CRM, Cyber systems, etc.”

I briefly got Jaluria on the phone yesterday, and he explained a bit more about why he thinks investors might see software as a decent place to hide out from the current chaos.

“With everything in the Middle East, you have to think about not just oil and gas input prices but also supply chains,” he said. “With software, you’re not really thinking about that.”

In other words, there is no equivalent of a closure of the Strait of Hormuz that software investors have to worry about.

Others suggested that the near-term profitability of these giant software companies — aside from concerns about potential long-term disruption from AI — may look different in the face of the economic uncertainty that seems to be growing with the war, especially after a sell-off that has left them relatively attractively valued.

Mark Moerdler, who covers software stocks for Bernstein Research, says that while the AI worries are clearly real, software companies continue to be highly productive cash cows.

“Everyone is afraid that AI is a massive disruptor, and all these articles you read talk about AI as massive disruptor or the world is ending or whatever,” he said. “You don’t see it in the fundamental numbers of the companies I cover. They are delivering GAAP profits, free cash flow, and they’re good investment ideas.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.